Pharmacovigilance leaders are routinely asked to justify their resourcing, by finance, by quality and, when it matters most, by an inspector. Too often the underlying logic is habit: the same writers on the same drugs, regardless of where safety signals actually concentrate.
Risk is not uniform
Across a portfolio, products carry very different signal loads. Allocating writer capacity evenly over-serves quiet products and starves high-risk ones, the exact inverse of what good safety governance requires.
Tier on real signal data
Computing reporting speed and seriousness rate per drug yields an objective Final Risk Tier, a consistent, data-backed classification that replaces subjective judgement and survives scrutiny.
Down to the activity
A tier is only useful if it drives a plan. Translating each tiered drug and PV activity into hours-per-day and monthly commitments by writer skill level turns risk into a concrete capacity plan, and eliminates over- and under-allocation.
Pharos Deploy
Pharos Deploy automates this end to end: objective drug tiering from signal frequency and seriousness, activity-level resource plans by writer skill mix, and capacity-planning output your team can hand to an auditor. It is the resourcing brain of the Pharos PV suite.
Ready to apply this thinking?
Start a pilot project and evaluate Ichelon's quality within one delivery cycle.